Transgene plots a course through the cancer vaccine graveyard
This article was originally published in Scrip
Executive Summary
French gene and cellular therapy company,Transgene, has developed a triple-pronged strategy that, the company hopes, will help its cancer vaccine, TG4010, steer successfully through clinical trial that are due to start later in 2011. Professor Angus Dalgleish, a key clinical advisor to Transgene, told Scrip at the company’s R&D day at the end of May that the key to avoiding earlier failures with cancer vaccines lay in judicious patient selection, early administration and their use in combination with radio and chemotherapy.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.